SGLT2 inhibitors are antihyperglycemic drugs that protect kidneys and the heart of patients
with or without type 2 diabetes and preserved or reduced kidney function from failing. The …

Cardiovascular disease is the leading cause of morbidity and mortality in diabetes. Recent
clinical studies indicate that sodium-glucose co-transporter 2 (SGLT2) inhibitors improve …

Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of
hospitalization for heart failure or death from cardiovascular causes among patients with …

Background The efficacy and safety of sodium–glucose cotransporter 2 inhibitors such as
sotagliflozin in preventing cardiovascular events in patients with diabetes with chronic …

Importance Patients with COVID-19 have a high prevalence of diabetes, and diabetes and
blood glucose control are determinants of intensive care unit admission and mortality …

Right ventricle (RV) dysfunction is the strongest predictor of mortality in pulmonary arterial
hypertension (PAH), but, at present, there are no therapies directly targeting the failing RV …

Pulmonary fibrosis (PF) is a life-threatening disorder that severely disrupts normal lung
architecture and function, resulting in severe respiratory failure and death. It has no definite …

Background SGLT2 inhibitors reduce the risk of heart failure (HF) mortality and morbidity,
regardless of the presence or absence of diabetes, but the mechanisms underlying this …

Abstract Sodium-glucose cotransporter-2 (SGLT2) inhibitors induce glycosuria, reduce
insulin levels, and promote fatty acid oxidation and ketogenesis. By promoting a nutrient …

Sodium-glucose cotransporter 2 inhibitors, which are recently introduced as glucose-
lowering agents, improve cardiovascular and renal outcomes in patients with diabetes …